论文部分内容阅读
研究乙肝导向干扰素对慢性乙型肝炎的治疗效果。应用北京靶向生物制品研究所试制的乙肝导向干扰素治疗慢性乙型肝炎１５例，同时设对照组１５例。结果显示，经乙肝导向干扰素治疗后，血清ＡＬＴ复常率为８６．６７％，优于对照组的４６．６７％，两组比较有显著性差异（Ｐ＜０．０１）。血清ＨＢｓＡｇ、ＨＢｅＡｇ、ＨＢＶＤＮＡ的阴转率分别为４０％、６０％、６６．６７％，均明显优于对照组（Ｐ＜０．０１）。提示乙肝导向干扰素对慢性乙型肝炎具有较好的疗效，而且与大剂量干扰素相对比，具有用量小、副作用小、费用低等优点，值得进一步探讨。
To study the therapeutic effect of hepatitis B-directed interferon on chronic hepatitis B Fifteen patients with chronic hepatitis B were treated with hepatitis B-guided interferon trial produced by Beijing Institute of Biological Products, meanwhile, 15 patients in control group. The results showed that after HBs-interferon treatment, the normal rate of serum ALT was 86.67%, which was better than 46.67% of the control group. There was a significant difference between the two groups (P <0.01). The negative conversion rates of serum HBsAg, HBeAg and HBVDNA were 40%, 60% and 66.67% respectively, which were significantly better than those of the control group (P <0.01). It is suggested that hepatitis B-directed interferon has a good curative effect on chronic hepatitis B, and has the advantages of small dosage, low side effects and low cost compared with high-dose interferon. It is worth further study.